Healthcare professional (HCP) engagement experienced significant shifts during the acute phase of the pandemic, as COVID-19 forced a rethink of traditional pharmaceutical sales and marketin
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh